{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:15:53Z","timestamp":1789215353576,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.2515\/therapie:2006011","type":"journal-article","created":{"date-parts":[[2007,4,19]],"date-time":"2007-04-19T10:58:49Z","timestamp":1176980329000},"page":"29-38","source":"Crossref","is-referenced-by-count":9,"title":["M\u00e9dicaments, maladie de Parkinson et syndromes parkinsoniens : actualit\u00e9s de pharmacovigilance"],"prefix":"10.1016","volume":"61","author":[{"given":"Jean-Louis","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Gony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Brefel-Courbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Senard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2006011_bb0010","first-page":"293","article-title":"Recent advances in the clinical pharmacology of Parkinson\u2019s disease","volume":"46","author":"Montastruc","year":"1991","journal-title":"Therapie"},{"key":"10.2515\/therapie:2006011_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.43.1_Part_1.1","article-title":"Neurosurgical horizons in Parkinson\u2019s disease","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"key":"10.2515\/therapie:2006011_bb0020","series-title":"Pharmacologie Clinique, Base de la Th\u00e9rapeutique","first-page":"1127","article-title":"Antiparkinsoniens","author":"Rondot","year":"1988"},{"key":"10.2515\/therapie:2006011_bb0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00002512-199609030-00003","article-title":"New directions in the drug treatment of Parkinson\u2019s disease","volume":"9","author":"Montastruc","year":"1996","journal-title":"Drugs Aging"},{"key":"10.2515\/therapie:2006011_bb0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatment of Parkinson\u2019s disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2006011_bb0035","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who where treated with ropinirole or levodopa","volume":"18","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie:2006011_bb0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (largo, lasting effect in agent therapy with rasagiline given once daily study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.2515\/therapie:2006011_bb0045","first-page":"420","article-title":"La Pharmacologie Sociale : une nouvelle branche de la Pharmacologie Clinique","volume":"57","author":"Montastruc","year":"2002","journal-title":"Therapie"},{"key":"10.2515\/therapie:2006011_bb0050","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","article-title":"Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole","volume":"52","author":"Frucht","year":"1999","journal-title":"Neurology"},{"key":"10.2515\/therapie:2006011_bb0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00002018-200225070-00001","article-title":"\u201cSleep attacks\u201d or \u201cunintended sleep episodes\u201d occur with dopamine agonists. Is this a class effect?","volume":"25","author":"Chaudhuri","year":"2002","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2006011_bb0060","first-page":"271","article-title":"Psychiatric complications of levodopa therapy of Parkinson\u2019s disease","volume":"40","author":"Nausieda","year":"1984","journal-title":"Adv Neurol"},{"key":"10.2515\/therapie:2006011_bb0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1472-8206.2003.00120.x","article-title":"Excessive daytime sleepiness and sleep attacks induced by entacapone","volume":"17","author":"Bares","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"10.2515\/therapie:2006011_bb0070","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","article-title":"Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson\u2019s disease","volume":"18","author":"Paus","year":"2003","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2006011_bb0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.10429","article-title":"Sleepiness in Parkinson\u2019s disease: a controlled study","volume":"18","author":"Brodsky","year":"2003","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2006011_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00002826-200105000-00013","article-title":"Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study","volume":"24","author":"Montastruc","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2006011_bb0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/00002018-200124110-00007","article-title":"Increased risk of somnolence with the new dopamine agonists in patients with Parkinson\u2019s disease. A meta-analysis of randomised controlled trials","volume":"24","author":"Etminan","year":"2001","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2006011_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002826-199901000-00004","article-title":"L-dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers","volume":"22","author":"Andreu","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2006011_bb0095","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1212\/WNL.58.3.460","article-title":"Effect of ropinirole on sleep onset: randomized, placebo-controlled study in healthy volunteers","volume":"58","author":"Ferreira","year":"2002","journal-title":"Neurology"},{"key":"10.2515\/therapie:2006011_bb0100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mds.10390","article-title":"Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson\u2019s disease","volume":"18","author":"Adler","year":"2002","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2006011_bb0105","first-page":"570","volume":"1 vol","author":"Billard","year":"1994"},{"key":"10.2515\/therapie:2006011_bb0110","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease in patients taking pergolide","volume":"77","author":"Pritchett","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.2515\/therapie:2006011_bb0115","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"10.2515\/therapie:2006011_bb0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","article-title":"Pergolide use in Parkinson\u2019s disease is associated with cardiac valve regurgitation","volume":"63","author":"Baseman","year":"2004","journal-title":"Neurology"},{"key":"10.2515\/therapie:2006011_bb0125","series-title":"Rapport de la Commission Nationale de PharmacoVigilance sur pergolide et valvulopathies cardiaques du 23 novembre","author":"Afssaps","year":"2004"},{"key":"10.2515\/therapie:2006011_bb0130","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","article-title":"Heart valvular disease in patients with Parkinson\u2019s disease treated with high-dose pergolide","volume":"61","author":"Van Camp","year":"2003","journal-title":"Neurology"},{"key":"10.2515\/therapie:2006011_bb0135","first-page":"186","article-title":"Fibrosis due to ergot derivatives: exposure to risk should be weighed up","volume":"11","author":"Prescrire Redaction","year":"2002","journal-title":"Prescrire Int"},{"key":"10.2515\/therapie:2006011_bb0140","first-page":"581","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine-phentermine","volume":"37","author":"Fitzgerald","year":"1997","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie:2006011_bb0145","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT 2 B receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medications","volume":"102","author":"Rothmann","year":"2000","journal-title":"Circulation"},{"key":"10.2515\/therapie:2006011_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0035-3787(04)70843-7","article-title":"Valvulopathies sous pergolide : la saga des fibroses dues aux d\u00e9riv\u00e9s de l\u2019ergot de seigle continue !","volume":"160","author":"Montastruc","year":"2004","journal-title":"Rev Neurol (Paris)"},{"key":"10.2515\/therapie:2006011_bb0155","first-page":"13","article-title":"Gasto en medicamentos y innovacion terapeutica","volume":"17","author":"Fundacio Institut Catala de Farmacologia","year":"2004","journal-title":"Butteli Groc"},{"key":"10.2515\/therapie:2006011_bb0160","first-page":"434","article-title":"Hypersexualit\u00e9 due aux m\u00e9dicaments dopaminergiques","volume":"25","author":"Prescrire Redaction","year":"2005","journal-title":"Rev Prescrire"},{"key":"10.2515\/therapie:2006011_bb0165","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-198910000-00002","article-title":"Hypersexuality with antiparkinsonian therapy","volume":"12","author":"Utti","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2006011_bb0170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/PL00007840","article-title":"Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson\u2019s disease","volume":"249","author":"Kanovsky","year":"2002","journal-title":"J Neurol"},{"key":"10.2515\/therapie:2006011_bb0175","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1345\/aph.1A412","article-title":"Possible zoophilia associated with dopaminergic therapy in Parkinson\u2019s disease","volume":"36","author":"Jimenez-Jimenez","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.2515\/therapie:2006011_bb0180","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00115-003-1505-6","article-title":"Sexual delinquency and Parkinson\u2019s disease","volume":"74","author":"Berger","year":"2003","journal-title":"Nervenarzt"},{"key":"10.2515\/therapie:2006011_bb0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002826-200207000-00008","article-title":"Reversible transvestic fetishism in a man with Parkinson\u2019s disease treated with selegiline","volume":"25","author":"Riley","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2006011_bb0190","series-title":"Psychopharmacology: the fourth generation of progress","first-page":"743","article-title":"The psychopharmacology of sexual behaviour","author":"Paus","year":"1995"},{"key":"10.2515\/therapie:2006011_bb0195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H","article-title":"Pathological gambling behaviour: emergence secondary to treatment of Parkinson\u2019s disease with dopaminergic agents","volume":"11","author":"Seedat","year":"2000","journal-title":"Depress Anxiety"},{"issue":"suppl 3","key":"10.2515\/therapie:2006011_bb0200","first-page":"125","article-title":"Compulsive gambling with dopaminergic therapy in Parkinson\u2019s disease","volume":"15","author":"Samanta","year":"2000","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2006011_bb0205","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson\u2019s disease: a behavioural manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2006011_bb0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00002826-200105000-00009","article-title":"Pathologic gambling in patients with Parkinson\u2019s disease","volume":"24","author":"Gschwandtner","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2006011_bb0215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s10072-004-0238-z","article-title":"Pathological gambling in two patients on dopamine replacement therapy for Parkinson\u2019s disease","volume":"25","author":"Avanzi","year":"2004","journal-title":"Neurol Sci"},{"key":"10.2515\/therapie:2006011_bb0220","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.10625","article-title":"Disabling repetitive behaviours in Parkinson\u2019s disease","volume":"19","author":"Kurlan","year":"2004","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2006011_bb0225","first-page":"441","article-title":"Comportement pathologique de jeu au cours d\u2019une maladie de Parkinson trait\u00e9e par l\u00e9vodopa et bromocriptine","volume":"159","author":"Montastruc","year":"2003","journal-title":"Rev Neurol (Paris)"},{"key":"10.2515\/therapie:2006011_bb0230","first-page":"675","article-title":"Des m\u00e9dicaments qui poussent au jeu pathologique","volume":"21","author":"Prescrire Redaction","year":"2001","journal-title":"Rev Prescrire"},{"key":"10.2515\/therapie:2006011_bb0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0014-2999(99)00372-6","article-title":"Drug addiction as dopamine-dependent associative learning disorders","volume":"375","author":"Di Chiara","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie:2006011_bb0240","first-page":"345","article-title":"Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene","volume":"7","author":"Perez de Castro","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.2515\/therapie:2006011_bb0245","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(03)00529-5","article-title":"Compulsive use of dopamine replacement therapy in Parkinson\u2019s disease: reward systems gone awry?","volume":"2","author":"Lawrence","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.2515\/therapie:2006011_bb0250","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1472-8206.1994.tb00808.x","article-title":"Drug-induced parkinsonism: a review","volume":"8","author":"Montastruc","year":"1994","journal-title":"Fundam Clin Pharmacol"},{"key":"10.2515\/therapie:2006011_bb0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2515\/therapie:2004021","article-title":"Les syndromes parkinsoniens m\u00e9dicamenteux","volume":"59","author":"Nguyen","year":"2004","journal-title":"Therapie"},{"key":"10.2515\/therapie:2006011_bb0260","first-page":"201","article-title":"Effets extrapyramidaux des antid\u00e9presseurs inhibiteurs de la recapture de la s\u00e9rotonine","volume":"21","author":"Prescrire R\u00e9daction","year":"2001","journal-title":"Rev Prescrire"},{"key":"10.2515\/therapie:2006011_bb0265","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2125.2001.01491.x","article-title":"Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa","volume":"54","author":"Van de Vijver","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie:2006011_bb0270","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00002826-200305000-00007","article-title":"Risk of serious extrapyramidal symptoms in patients with Parkinson\u2019s disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs","volume":"26","author":"Gony","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2006011_bb0275","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/mds.870100325","article-title":"Does fluoxetine aggravate Parkinson\u2019s disease? A pilot prospective study","volume":"10","author":"Montastruc","year":"1995","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2006011_bb0280","first-page":"629","article-title":"D\u00e9mence et troubles extrapyramidaux sous acide valpro\u00efque au long cours","volume":"55","author":"Masmoudi","year":"2000","journal-title":"Therapie"},{"key":"10.2515\/therapie:2006011_bb0285","first-page":"835","article-title":"Syndrome d\u00e9mentiel reversible d\u00fb \u00e0 l\u2019acide valpro\u00efque","volume":"23","author":"Redaction Prescrire","year":"2003","journal-title":"Rev Prescrire"},{"key":"10.2515\/therapie:2006011_bb0290","first-page":"392","article-title":"Parkinsonismo por trimetazidine","volume":"19","author":"Marti-Masso","year":"2004","journal-title":"Neurologia"},{"issue":"8","key":"10.2515\/therapie:2006011_bb0295","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.20574","article-title":"Trimetazidine: a new cause for drug-induced parkinsonism?","volume":"20","author":"Sommet","year":"2005","journal-title":"Mov Disord"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716303626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716303626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T02:58:38Z","timestamp":1554260318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716303626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0040595716303626"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2006011","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}